Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Каталог · ЕАЭС

Клинические исследования и проекты

Sanofi · найдено 123

Sanofi
Ищем по всем вариантам написания в реестрах, по-русски и по-английски. Спонсор или разработчик.
Статус
Что исследуют
Источник
Фаза
Страна
Участники
Кто может участвовать По критериям ClinicalTrials.gov. Исследования, где реестр возраст и пол не указывает, тоже показываются. Возраст и пол нигде не сохраняются.
Сбросить
123 исследования
Завершено Фаза III Россия
cabazitaxel (XRP6258) (RPR116258); mitoxantrone; prednisone · Sanofi

A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen

Москва 1 центр 755 участников во всех странах ClinicalTrials.gov EFC6193
Завершено Фаза III Россия
Lixisenatide (AVE0010); Placebo; Basal Insulin; Metformin · Sanofi

A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin

496 участников во всех странах ClinicalTrials.gov EFC6016
Завершено Фаза III Россия
Insulin Glargine; Insulin Glulisine; Metformin; insulin secretagogue · Sanofi

Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs

Москва 1 центр 811 участников во всех странах ClinicalTrials.gov HMR1964A_3506
Завершено Фаза III Россия
Enoxaparin sodium; Semuloparin sodium; Placebo · Sanofi

A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery

1 003 участника во всех странах ClinicalTrials.gov EFC10343
Завершено Фаза III Россия
Aflibercept; Placebo (for aflibercept); Docetaxel; Prednisone or Prednisolone · Sanofi

A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer

1 224 участника во всех странах ClinicalTrials.gov EFC6546
Завершено Фаза III Россия
docetaxel, doxorubicin, cyclophosphamide; Docetaxel,doxorubicin, cyclophosphamide · Sanofi

A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes

Москва 1 центр 3 299 участников во всех странах ClinicalTrials.gov TAX_GMA_301
Завершено Фаза III Россия
Teriflunomide (HMR1726) · Sanofi

Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses

742 участника во всех странах ClinicalTrials.gov LTS6050
Завершено Фаза III Россия
Enoxaparin sodium (XRP4563) · Sanofi

A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy

20 506 участников во всех странах ClinicalTrials.gov EFC6147
Завершено Фаза II–III Россия
CELIVARONE (SSR149744C) · Sanofi

Placebo Controlled Double Blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200, or 300 mg OD, With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter

673 участника во всех странах ClinicalTrials.gov DRI5165
Завершено Фаза IV Россия
Insulin Glargine · Sanofi

Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes

Москва 1 центр 390 участников во всех странах ClinicalTrials.gov HOE901_4042
Завершено Фаза III Россия
Fexofenadine · Sanofi

A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma

Москва 1 центр 1 000 участников во всех странах ClinicalTrials.gov M016455P/3002
Завершено Фаза III Россия
Glimepiride+metformin (Amaryl M®) - HOE4900 · Sanofi

A Multinational, Open Label, Non Comparative, 24-week Study to Evaluate the Blood Glucose Lowering Efficacy and Safety of a Fixed Dose Combination of Glimepiride and Metformin in Patients With Inadequately Controlled Type 2 Diabetes

167 участников во всех странах ClinicalTrials.gov GLMET_R_05823
Завершено Фаза II Россия
Nolpitantium besylate · Sanofi

Nolpitantium Besylate in Patients With Mild to Moderate Ulcerative Colitis, a Double-Blind, Placebo Controlled Efficacy and Safety, 8 Week Study

307 участников во всех странах ClinicalTrials.gov DRI4553
Завершено Россия
Dupilumab SAR231893 · Sanofi

PRospEctiVe charactErization of Asthma Patients Treated With DupilumAb in reaL World Setting

376 участников во всех странах ClinicalTrials.gov OBS16688
Завершено Фаза III Россия
Idrabiotaparinux sodium; Idraparinux sodium; Avidin; Placebo (for Avidin) · Sanofi

International, Multicenter, Randomized, Parallel Group, Double-blind Study, in Patients With Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs, Demonstrating the Bioequipotency at Steady State of Equimolar Doses of SSR126517E (3.0 mg) Once a Week and SR34006 (2.5 mg) Once a Week, Documenting the Safety and Efficacy of Both Compounds During a 6-month Treatment, and Demonstrating the Neutralizing Effect of SSR29261 on the SSR126517E-induced Anti-Xa Activity

Москва 1 центр 757 участников во всех странах ClinicalTrials.gov EFC5945
Прекращено Фаза III Россия
SR58611A · Sanofi

A Double-Blind Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A Versus Placebo in the Prevention of Relapse of Anxiety up to 1 Year in Patients With GAD Improved After 12 Weeks of Open Label Treatment With SR58611A.

257 участников во всех странах ClinicalTrials.gov LTE5894
Завершено Фаза III Россия
Lixisenatide (AVE0010); Placebo · Sanofi

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 12-week Study Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Not Treated With Antidiabetic Agents

361 участник во всех странах ClinicalTrials.gov EFC6018
Прекращено Фаза III Россия
Rimonabant; Placebo (for Rimonabant); Metformin · Sanofi

A Randomized, Double Blind, Placebo Controlled Study Evaluating the Glycemic Effect of Rimonabant Added to Metformin in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy

403 участника во всех странах ClinicalTrials.gov EFC10518
Завершено Фаза IV Россия
Insulin Glargine (HOE901) [Lantus]; Glimepiride; human insulin [NPH] · Sanofi

Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled

708 участников во всех странах ClinicalTrials.gov LANTU_C_02762
Завершено Фаза III Россия
saredutant (SR48968); paroxetine; placebo · Sanofi

An Eight-week, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Saredutant (100 mg and 30 mg) Once Daily in Combination With Paroxetine 20 mg Once Daily Compared to Saredutant Placebo in Combination With Paroxetine 20 mg Once Daily in Patients With Major Depressive Disorder

825 участников во всех странах ClinicalTrials.gov EFC10438

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.